AstraZeneca snags Tagrisso 'breakthrough' in first-line EGFR lung cancer patients
admin 19th December 2017 Uncategorised 0Back in September, AstraZeneca’s Tagrisso posted data showing it could outdo the competition in treating first-line, EGFR mutation-bearing lung cancer patients. And now, the FDA is helping the drug speed toward an approval in that population.
More: AstraZeneca snags Tagrisso 'breakthrough' in first-line EGFR lung cancer patients
Source: fierce